Single Pharmaceutical-Based Strategy Aims to Solve Neurological and Psychiatric Disorders

(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 10/19/11 -- One pharmaceutical company, Cortex Pharmaceuticals (OTCBB: CORX) is now engaged in a tireless quest to treat a wide variety of ailments that range in symptoms and complexity from Parkinson's Disease and Fragile X syndrome to ADHD and obstructive sleep apnea.

An exclusive Q&A with Mark Varney, President and CEO of Cortex Pharmaceuticals, reveals details about research by Cortex and its collaborators, including how Professors Gary Lynch and Christine Gall from the University of California, Irvine, have demonstrated that certain compounds may restore function to previously damaged areas of the brain.

The exclusive report is now available at:



In addition, investors may access BioMedReports' for use as a tool in more profitable trading by visiting:



News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com





Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 19.10.2011 - 11:36 Uhr
Sprache: Deutsch
News-ID 77737
Anzahl Zeichen: 0

contact information:
Town:

LOS ANGELES, CA

Kategorie:

Investment Opinion

Diese Pressemitteilung wurde bisher 179 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Single Pharmaceutical-Based Strategy Aims to Solve Neurological and Psychiatric Disorders"
steht unter der journalistisch-redaktionellen Verantwortung von

BioMedReports (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Why Zalicus (ZLCS) Shares Could Make a Big Move in the Days Ahead ...

LOS ANGELES, CA -- (Marketwired) -- 11/06/13 -- In case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a huge binary event from Zalicus, Inc. (NASDAQ: ZLCS); a NASDAQ listed bioph ...

Discounted Price Levels Make CEL-SCI Shares a Solid Speculative "Buy" ...

LOS ANGELES, CA -- (Marketwired) -- 08/01/13 -- With shares trading at heavily discounted price levels, speculative investors looking for a good bottom bounce trade should have their sights set on CEL-SCI Corporation (NYSE MKT: CVM) who last provide ...

Q&A With Coronado Biosciences CEO Harlan Weisman, M.D. ...

LOS ANGELES, CA -- (Marketwired) -- 07/23/13 -- It has been over a year since Coronado Biosciences, and the company, so we thought it time for an updated Q&A on this biopharmaceutical company that continues to be one of biotech's most talk ...

Alle Meldungen von BioMedReports